LONGEVITY Project Blog

World Tuberculosis Day 2024: An update of our work at CROIWorld Tuberculosis Day 2024: An update of our work at CROI

World Tuberculosis Day 2024: An update of our work at CROI

Every 24 March we commemorate World TB Day with the World Health Organisation. The theme for 2024 is ‘Yes! We can stop TB!’ and we wanted to update you on how we are playing our part in making that statement a reality.

Posted on: 22 March 2024

CELT celebrates Healthcare Science Week 2024 with Professor Saye KhooCELT celebrates Healthcare Science Week 2024 with Professor Saye Khoo

CELT celebrates Healthcare Science Week 2024 with Professor Saye Khoo

Healthcare Science Week is a week dedicated to celebrating the work of over fifty scientific specialisms and professional groups that make up the National Health Service’s diverse workforce.

Posted on: 15 March 2024

Invest, Innovate and Implement – How LONGEVITY can help deliver ZERO malariaInvest, Innovate and Implement – How LONGEVITY can help deliver ZERO malaria

Invest, Innovate and Implement – How LONGEVITY can help deliver ZERO malaria

World Malaria Day was established to provide education and understanding of malaria. Each year the Centre of Excellence for Long-acting Therapeutics (CELT) takes this opportunity to reaffirm our commitment to revolutionising malaria prevention and control to reduce the malaria burden in low- and middle-income countries (LMICs). The theme this year is “Time to deliver zero malaria: invest, innovate, implement” – Three aspects that are critical to our strategy to reduce the malaria burden.

Posted on: 24 April 2023

Fighting on the front-line – Empowering communities to drive long-acting injectable innovationFighting on the front-line – Empowering communities to drive long-acting injectable innovation

Fighting on the front-line – Empowering communities to drive long-acting injectable innovation

The latest WHO World Malaria Report indicates that Africa carries a disproportionately high burden of malaria with 95% of malaria cases and 96% of malaria deaths occurring in this region with children under 5 accounted for about 80% of all malaria deaths on the continent. It is now more important than ever that more investment in innovation and implementation of more effective prevention strategies for low- and middle-income countries.

Posted on: 24 April 2023

Dynamic partnerships for maximum impact: How our collaboration with Tandem Nano Ltd is fast-tracking our development programmeDynamic partnerships for maximum impact: How our collaboration with Tandem Nano Ltd is fast-tracking our development programme

Dynamic partnerships for maximum impact: How our collaboration with Tandem Nano Ltd is fast-tracking our development programme

Maintaining adherence to medication is often a huge challenge to patients in low- and middle-income countries (LMICs). Reasons for poor adherence can be quite complex. They may run out of tablets and are unable to get a new supply, they may forget to take their medicine or they simply don’t like taking tablets daily due to the difficult side effects they can cause. Regardless of the reason for poor adherence, there is overwhelming evidence that supports the need for a different approach to healthcare within affected communities.

Posted on: 5 April 2023

Stopping TB in its tracks with long-acting injectables: A war of attritionStopping TB in its tracks with long-acting injectables: A war of attrition

Stopping TB in its tracks with long-acting injectables: A war of attrition

World TB Day 2023, themed 'Yes! We can end TB!', is set to inspire a renewed sense of hope in the fight against the TB epidemic. The campaign seeks to encourage leaders to take bold steps, increase funding, adopt innovative solutions, and act faster to curb the spread of the disease.

Posted on: 23 March 2023

Community engagement – shaping the long-acting technologies pipelineCommunity engagement – shaping the long-acting technologies pipeline

Community engagement – shaping the long-acting technologies pipeline

The latest World Health Organisation (WHO) reports estimate 58 million people globally have chronic hepatitis C virus (HCV) infection, with about 1.5 million new infections occurring per year. 75% of these cases occur in low- and middle-income countries. It is estimated that oral drugs at the point of diagnosis provide a 98% cure rate if an entire oral regimen is completed. However, in LMICs, access to medication can be complex with issues around stigma and pill burden resulting in poor completion rates.

Posted on: 28 July 2022

Developing a single-injection cure for hepatitis C virus for low- and middle-income countriesDeveloping a single-injection cure for hepatitis C virus for low- and middle-income countries

Developing a single-injection cure for hepatitis C virus for low- and middle-income countries

Dr. David Lee Thomas is a professor of medicine at the Johns Hopkins University School of Medicine. He is trained in internal medicine and infectious diseases and cares for patients with chronic viral hepatitis. Dave leads the Hepatitis C programme for the Unitaid funded LONGEVITY project for CELT. From 2006-2022, Dr. Thomas served as the director of the Division of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine. He remains a Professor of Medicine in the School of Medicine and of Epidemiology in the Bloomberg School of Public Health. He is a co-director of the Centre for AIDS Research Clinical Core. For world Hepatitis Day 2022, Dr Thomas shared his expertise on Hepatitis C virus as a world-leading clinical researcher.

Posted on: 28 July 2022

Saving lives through long-acting injectable innovationSaving lives through long-acting injectable innovation

Saving lives through long-acting injectable innovation

Professor Steve Rannard is Co-director of the Centre of Excellence for Long-acting Therapeutics. Steve leads a team of chemists in developing long-acting formulations for malaria prevention. For World Malaria Day, Steve and his group spent some time to explain how their innovative technology can revolutionise malaria prevention in low- and middle-income countries.

Posted on: 24 April 2022

Blog